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Abstract: Cancer is a disease associated with genomic instability and mutations. Excluding 
some tumors  with specific  chromosomal translocations, most  cancers  that develop  at an 
advanced age are characterized by either chromosomal or microsatellite instability. However, 
it is still unclear how genomic instability and mutations are generated during the process of 
cellular  transformation  and  how  the  development  of  genomic  instability  contributes  to 
cellular transformation. Recent studies of cellular regulation and tetraploidy development 
have provided insights into the factors triggering cellular transformation and the regulatory 
mechanisms that protect chromosomes from genomic instability. 
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1. Introduction 
During  cancer  development,  cells  acquire  immortality  in  association  with  the  development  of 
genomic instability [1–3] and mutations in certain genes including those of the Arf/p53 pathway [4–7]. 
Except  for  certain  tumors  associated  with  specific  chromosomal  translocations  [8],  such  as  infant 
leukemia and sarcoma [9–13], most cancers that develop at an advanced age [14–22] are characterized 
by an unstable genome, with either chromosomal instability (CIN) or microsatellite instability (MIN) [23], 
and  specific  mutations  [24]  (Figure  1).  Although  MIN  usually  develops  on  a  mismatch  repair  
(MMR)-deficient background [25–29], CIN frequently develops in the presence of a functional MMR 
system [23]. While cancer cells with MIN are rarely associated with aberrant chromosomes, cancer 
cells with CIN are characterized by a diversity of chromosomal abnormalities such as aneuploidy; 
chromosome-loss, -translocation, and -gain; gene amplification; and loss of heterozygosity [30,31]. 
Similar to the process of in vivo carcinogenesis, cells immortalized in vitro show genomic instability 
with either CIN or MIN and mutations in the Arf/p53 module [32]. Furthermore, CIN is inducible on a 
normal genetic background [33]. These in vitro findings illustrate the critical role of genomic instability 
and loss of Arf/p53 function in the acquisition of immortality, and raise the following critical questions: 
how is genomic instability induced and how does it contribute to cellular transformation? What is the 
role of the Arf/p53 module in cancer suppression? This review examines recent evidence regarding the 
oncogenic stress-induced development of tetraploidy and the role of the Arf/p53 module in suppressing 
cellular transformation. 
2. Massive Genomic Rearrangements during Cellular Transformation are Associated  
with Tetraploidization 
Recent advances in DNA sequencing have helped to identify genomic rearrangements associated 
with  tumorigenesis  and  have  revealed  the  diversity  of  cancer  cell  genomes  [30,34–37].  Although 
genomic  rearrangements  and  mutations  in  cancer  have  traditionally  been  thought  to  accumulate 
gradually over time, a recent report analyzed cancer cells with complex rearrangements and showed 
that massive genomic rearrangements can occur during a single catastrophic event [37–40]. Although 
the exact mechanisms underlying such catastrophic events are still unclear, the accumulated findings 
suggest that one such event could be associated with tetraploidization. In fact, tetraploid cells have 
been documented in the early stages of colorectal, breast, and cervical cancer [41,42] and also precancerous 
lesions [43]. By contrast, the genomes of most malignant cancer cells with CIN are characterized by 
aneuploidy.  Therefore,  after  massive  genomic  rearrangement  in  association  with  tetraploidization, 
transformed cells might continuously change the chromosomal status to become aneuploid [44]. 
Oxidative  stress-induced  senescence  in  normal  mouse  embryonic  fibroblast  cells  (MEFs)  [45]  
can lead to the acquisition of immortality [46] and mutations in the Arf/p53 module [32] as well as 
CIN [33], in a process analogous to that observed during cancer development. In agreement with the 
hypothesis  that  tetraploidization  is  one  of  the  catastrophic  events  that  triggers  massive  genomic 
rearrangements,  MEF  immortality  occurs  with  the  acquisition  of  tetraploidy  and  mutation  of  the 
Arf/p53  module  [33]  (Figure  1A).  In  addition,  immortalized  tetraploid  MEFs  eventually  become 
aneuploid  during  serial  cultivation  [33,47],  similar  to  the  changes  observed  in  cancer  cells  [44]. Int. J. Mol. Sci. 2012, 13  6494 
 
 
Identical  tetraploidization  and  the  subsequent  aneuploidization  were  also  observed  in  some  other 
models [48,49]. Thus, ―tetraploidy development‖ is likely involved in the events triggering cellular 
transformation and the ensuing genomic instability. Importantly, as tetraploidy is observed in the in vivo 
precancerous states [50], in vitro tetraploidization occurs prior to the acquisition of immortality, during 
a period  in  which MEFs  rarely proliferate and  inevitably  exhibit  accumulated  γH2AX foci  and a 
senescent appearance, i.e., a flattened and enlarged morphology [33]. 
Figure  1.  Development  of  genomic  instability  prior  to  cellular  transformation.  Most 
cancers that arise in aging organs and cells transformed in vitro develop due to mutations, 
such as those in the Arf/p53 module, and genomic instability, with either chromosomal 
instability (CIN) (A) or microsatellite instability (MIN) (B). Whereas MIN is associated 
with a mismatch repair-deficient background, CIN can also develop on a normal genetic 
background.  In  normal  mouse  embryonic  fibroblast  cells  (MEFs),  tetraploidy  develops 
prior  to  the  acquisition  of  immortality  and  causes  mutations  in  the  Arf/p53  module. 
Immortalization of MEFs is initially associated with tetraploidy and eventually changes to 
aneuploidy. By contrast, mismatch repair-deficient cells maintain chromosomal stability 
during transformation, but MIN develops in the transformed cells. 
 
Although  multiple  mechanisms  of  tetraploidy  development  have  been  reported  [44],  the  
main  tetraploidization  process  leading  to  cancerous  transformation  is  most  likely  a  failure  of  
chromosome-bridge-mediated  cytokinesis  [51–53],  which  primarily  results  in  bi-nucleated  
tetraploidy [33,54]. This is because (1) chromosome-bridge formation is associated with DNA lesions 
induced by oncogene acceleration and aberrant growth activation during pre-cancerous stages [55,56]; 
and (2)  other  tetraploidization processes, such as  cell-to-cell fusion and mitotic slippage-mediated 
tetraploidization [57–60] do not induce mutations and massive genomic rearrangements in a single 
catastrophic event (chromothripsis) [37–40]; however, chromosome-bridge mediated tetraploidization 
does. In fact, the process of chromosome-bridge mediated tetraploidization is associated with DNA Int. J. Mol. Sci. 2012, 13  6495 
 
 
damage under a repair defective background, directly inducing aberrations in the genome. Oncogenic 
stress can be reproduced in vitro by oncogene activation and exogenous growth stimulation due to 
accelerated S phase entry and the resulting DNA replication stress [55,56]. Importantly, cells subjected 
to oncogenic stress develop tetraploidy [33] despite being under the opposing influences of cancer 
progression, reflected by senescence and apoptosis induction [61]. In agreement with the argument 
supporting aging-associated cancer development with CIN, many senescent cells and aging organs 
show persistent DNA damage [62,63]. 
In response to oncogenic DNA replication stress-associated lesions, cells activate damage checkpoint 
responses and downstream barrier reactions, such as senescence and apoptosis induction [55,56,64]. 
However, induced DNA lesions are not efficiently repaired and, thus, are often carried over into M 
phase without completion of the repair process (Figure 2A). This causes chromosome-bridge formation 
upon missegregation of chromosomes during mitosis, which leads to cytokinesis failure and tetraploidy 
development  [33].  Although  the  induced  tetraploidy  is  initially  bi-nucleated,  this  is  only  transient 
because the chromosomes of two nuclei assemble on the same M phase plate and then segregate to 
each side, leading to the formation of two single-nucleus tetraploids at the following G1 phase [33] 
(Figure 2A). In fact, prior to the acquisition of immortality, senescent MEFs cultured using the 3T3 
protocol [46] often show chromosome-bridge formation and accumulation of bi-nucleated tetraploid 
cells  [33,54]  (Figure  2B).  Immortalized  MEFs  are  subsequently  generated,  which  have  a  mutated 
Arf/p53 module (either in Arf or p53) [32] in association with tetraploidy [33] (Figures 1A and 2C). In 
these  immortalized  MEFs,  the  loss  of  senescent  morphology  and  the  acquisition  of  primary-like 
phenotypes in terms of morphology and growth activity (Figure 2D) become predominant (Figure 2D). 
During  these  processes,  tetraploidization  occurs  in  rarely-growing  senescent  cells.  In  contrast,  the 
emergence  of  immortality  is  associated  with  the  loss  of  senescent  characteristics;  the  resulting 
immortalized cells, therefore, gain growth activity and an altered morphology. 
3. Mutation Induction during the Development of Tetraploidy 
In addition to developing genomic instability, cancer cells accumulate a number of mutations [24], 
although only a few may be required for carcinogenesis. The mutations essential for carcinogenesis 
include at least the following two types: (a) tissue-specific mutations, such as mutations in the APC 
regulation module in the colon [65]; and (b) mutations in the Arf/p53 module, which are likely to be 
common mutations in malignant cancer cells [32]. Importantly, unlike the tissue specific mutations 
observed in cancer, the Arf/p53 module is also mutated in cells immortalized/transformed in vitro [32]. 
This indicates that the Arf/p53 module is involved in cellular regulatory pathways that are common to 
various tissues. 
Although the mechanisms underlying the induction of mutations in the Arf/p53 module are still 
unclear,  an  in  vitro  model  suggests  that  they  are  the  direct  consequence  of  tetraploidization  [47] 
(Figure 2E). In fact, whereas immortality acquisition in normal MEFs occurs only with tetraploidy and 
mutations in the Arf/p53 module, p53-knockout MEFs immortalize while diploid [47]. This suggests 
that  tetraploidization  is  necessary  for  immortalization  of  wild-type  MEFs  with  mutations  in  the 
Arf/p53 module, but  not  for  the development  of  immortality  (as  long as  p53 function is lost). In 
addition, wild-type MEFs cannot develop immortality with genome stability [47] under conditions in Int. J. Mol. Sci. 2012, 13  6496 
 
 
which the Arf/p53 module is continuously functional. These lines of evidence indicate that tetraploidy 
development  directly  contributes  to  mutation  induction  in  the  Arf/p53  module,  and  tetraploidy 
develops prior to the acquisition of immortality in barely-proliferating normal MEFs. 
Figure  2.  Process  of  tetraploidization  and  immortality  acquisition.  (A)  Model  of  the 
tetraploidization process with the subsequent emergence of immortality. Oncogenic stress 
induced by oncogene activation or aberrant growth stimulation leads to the accumulation of 
DNA replication stress-associated lesions in cells and accelerated entry into S phase. These 
DNA lesions are not efficiently repaired, and are thereby carried over into M phase and 
mediate chromosomal-bridge formation, which leads to tetraploidy development after the 
failure  of  cytokinesis.  The  resulting  tetraploidy  is  initially  associated  with  two  nuclei  
(bi-nucleated tetraploidy) until the next M phase, in which chromosomes assemble on the 
same M phase plate to develop single-nucleated tetraploidy in the subsequent G1 phase; (B) 
MEFs in the senescent stage show accumulated bi-nucleated tetraploidy. Nuclei are stained 
with  DAPI.  Red  double  arrowheads  indicate  bi-nucleated  tetraploid  cells;  
(C) Images showing the induction of chromosomal instability after immortality acquisition; 
(D) The emergence of immortality is usually observed in morphologically senescent MEFs. 
Colonies  of  immortalized  MEFs  are  generated  from  morphologically  senescent  MEFs 
(flattened  and  enlarged  morphology).  Such  immortalized  MEFs  eventually  become 
predominant; (E) Steps leading to senescence and immortalization of normal MEFs are 
schematically described along with the chromosomal status at each step. 
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4. Arf/p53 Module-Dependent Quiescent Cellular Status 
Similar to the process of development of malignant cancers, mutations in the Arf/p53 module are 
widely induced during immortality acquisition in vitro [32,33,47]. However, the exact role of Arf/p53 
in the suppression of cellular transformation is still unclear. A recent study shows that most of the 
direct transcription targets of p53 are associated with the acute DNA damage response, but are not 
required for tumor suppression (Figure 3), suggesting two separate functions for p53 [66]. In addition, 
Arf and p53, the two most frequently mutated genes in cancer, are part of the same MDM2-mediated 
regulatory module and are mutated in a mutually exclusive manner [4]. This strongly suggests that the 
essential  role  of  p53  in  cancer  suppression  is  dependent  on  Arf  regulation,  and  that  cells  acquire 
immortality  only  in  the  presence  of  mutations  in  Arf  and  p53.  By  contrast,  p53-dependent  acute 
damage responses are even observed in cancer cells, indicating that cancer cells without p53 mutations 
are more sensitive to DNA damaging agents than p53-mutated cancer cells. Thus, unlike Arf-independent 
p53 activation (e.g., through checkpoint responses), the role of p53 in cancer suppression is likely to be 
regulated by Arf. 
Figure  3.  p53  plays  two  distinct  roles  in  the  acute  DNA  damage  response  and  the 
establishment of quiescent cellular status. Whereas damaged cells show acute responses 
and  often  undergo  premature  senescence  and  apoptosis,  normal  cells  spontaneously 
become  growth-arrested  under  the  regulation  of  Arf/p53  under  conditions  in  which  a 
quiescent state is induced. This quiescent cellular status is under the functional regulation 
of the Arf/p53 module but, unlike in cells undergoing acute damage responses, does not 
involve p53 accumulation. 
 
Because Arf and p53 are critical tumor suppressors, Arf- and p53-knockout (KO) mice show a 
significantly increased predisposition to cancer [67,68]. By contrast, transgenic mice with additional 
single gene copies of Arf and p53 are characterized by cancer suppression and an extended lifespan [32], 
indicating normal regulation of the Arf/p53 genes. However, unlike mice that show functional Arf and 
p53 regulation, transgenic mice with hyper-active p53 with no MDM2-binding site show a reduced 
lifespan and premature aging [69–71]. In these mice, p53 is not regulated by Arf because the normal 
MDM2-mediated inhibition of Arf is absent. Thus, unlike its stress response-associated function, under 
normal conditions the Arf/p53 module functions simultaneously to extend lifespan and suppress cancer. 
Importantly, the two functions of p53 are distinguished by differences in p53 levels; i.e., (1) hardly-
detectable levels of p53 under normal conditions are associated with extended lifespan and cancer Int. J. Mol. Sci. 2012, 13  6498 
 
 
suppression; and (2) accumulated p53 is associated with premature aging and with senescent and/or 
apoptotic cells [55,56], which are also characterized by p53 overexpression [72].  
Arf is coded on the same gene locus as another cancer suppressor, INK4a. Therefore, mutations in 
Arf may affect INK4a expression. However, unlike INK4a-KO mice, Arf-KO mice show spontaneous 
tumor development, as do p53-KO mice [73]. Furthermore, unlike INK4a-KO MEFs, which senesce in 
a similar manner to wild-type MEFs, primary Arf-KO MEFs directly acquire immortality in a manner 
similar to p53-KO MEFs [73]. Thus, unlike INK4a, Arf (along with p53) is involved in  essential 
cellular regulatory functions that induce growth-arrest. 
5. Cellular Quiescence Is Produced with Arf/p53-Dependent H2AX Diminution 
The exact contribution of the Arf/p53 module to growth arrest is unclear. We recently determined 
that normal cells show decreased H2AX levels after serial proliferation under the regulation of the 
Arf/p53 module, which contributes to growth arrest [47]. In agreement with this, cells in which H2AX 
was  either  knocked-down  or  knocked-out  show  severe  growth  retardation  [74–81].  Importantly, 
decreased  H2AX  levels  are  also  observed  in  adult  mouse  organs,  such  as  liver,  spleen,  and  
pancreas, in which cells rarely proliferate [47]. On the other hand, the mechanisms underlying H2AX 
downregulation are absent in cancer cells due to mutations in the Arf/p53 module.  
Figure 4. Arf/p53-dependent decrease of H2AX contributes to the characteristics of the 
growth-arrested  state.  Normal  cells  in  a  growth-arrested  state  due  to  a  decrease  in  
Arf/p53-dependent H2AX levels show similar characteristics to cells in which H2AX is 
either  knocked-out  or  knocked-down  (A).  However,  these  growth-arrested  states  are 
discriminated  by  either  a  marked  decrease  in  H2AX  levels  or  by  the  accumulation  
of  γH2AX  (B),  resulting  in  either  continuous  quiescence  or  tetraploidization  and 
immortalization, respectively. 
 
Intriguingly,  certain  characteristics  of  senescent  cells  and  growth-arrested  cells  may  be  the  
result  of  Arf/p53-dependent  H2AX  downregulation,  because  cells  without  H2AX  show  the  same 
characteristics,  including  growth  retardation  and  defects  in  DNA  damage  repair  and  checkpoint 
responses (Figure 4A) [74–81]. Therefore, cells showing Arf/p53-dependent H2AX downregulation 
are sensitive to accelerated growth stimulation by exogenous stresses, which leads to the development 
of tetraploidy (Figure 2A). This includes the effects of preserving the quiescent state and the risk of 
developing genomic instability [47] (Figure 4B). During cell maintenance (with occasional growth-arrest), 
cells enter a quiescent state, in which H2AX is largely downregulated. This quiescent cellular state is 
preserved  under  the  functional  regulation  of  the  Arf/p53  module  and  the  maintenance  of  genome 
stability  [47].  On  the  other  hand,  cells  under  continuous  growth  stimulation  accumulate  DNA Int. J. Mol. Sci. 2012, 13  6499 
 
 
replication stress-associated lesions and exhibit γH2AX because they undergo accelerated entry into S 
phase [47]. In addition, cells showing a reduced level of H2AX are defective in DNA damage repair 
and  DNA  damage  checkpoint  responses  [47]. These  unrepairable  DNA  lesions  are  not  efficiently 
removed  and  are  carried over into M  phase, causing tetraploidization and, subsequently,  inducing 
mutations in the Arf/p53 module (Figure 2A), which lead to recovery of H2AX expression and growth 
activity  and  the  acquisition  of  immortality.  Taken  together,  growth  arrest  in  normal  cells  can  be 
separated into two states [47]: (1) a continuously quiescent state with largely downregulated H2AX 
under genome stability maintenance; and (2) a state at risk of developing tetraploidy with γH2AX 
accumulation. Although the regulatory mechanisms that lead to the different cellular states are still 
unclear, our recent results demonstrate that growth stimulation is involved [47]. 
Figure 5. Life cycle of normal cells. Normal cells show high expression of H2AX in the 
early stages along with active proliferation, followed by growth retardation. As senescence 
progresses (after serial cell proliferation), H2AX levels decrease under the regulation of the 
Arf/p53 module. Because such a growth-arrested state is a consequence of Arf/p53-dependent 
H2AX downregulation, growth-arrested cells are also defective in DNA damage repair and 
checkpoint  responses.  These  cells,  which  are  also  at  risk  of  genomic  instability  under 
conditions of exogenous growth stimulation, subsequently develop tetraploidy and mutations 
in  the Arf/p53 module.  This  leads  to  a recovery  of H2AX levels  and  growth activity, 
resulting  in  the  acquisition  of  immortality.  By  contrast,  cells  that  maintain  genomic 
stability  preserve  their  quiescent  status.  Because  normal  cells  undergo  growth-arrest 
associated  with  downregulation  of  H2AX,  which  is  regulated  by  the  Arf/p53  module, 
exogenous growth stimulation is critical for either homeostasis or for the development of 
tetraploidy and immortality. 
 
After serial cell proliferation, cells enter a growth-arrested state associated with Arf/p53-dependent 
downregulation of H2AX (Figure 5). By contrast, cells subjected to stress by oncogenes and growth 
stimuli are characterized by persistent exhibition of γH2AX [55,56], which is also a characteristic  
of senescent cells and aging organs where it is induced by a variety of stresses [14–22]. However,  
Arf/p53-dependent downregulation of H2AX is often abrogated during the development of cancer, as 
well as during in vitro cellular transformation associated with mutations in the Arf/p53 module [74–81]. Int. J. Mol. Sci. 2012, 13  6500 
 
 
To  suppress  cellular  transformation,  normal  cells  generally  enter  a  growth-arrested  state  and 
downregulate H2AX in an Arf/p53-dependent manner; immortality is, therefore, inevitably associated 
with Arf/p53 mutations, which are triggered by genomic instability. The mechanism(s) underlying the 
involvement of the Arf/p53 module in H2AX downregulation is still unclear. H2AX is probably not the 
direct target of p53 because the promoter region of H2AX does not contain a p53-binding site. In 
addition, Arf/p53 might not be the only mechanism by which H2AX is downregulated because miR24, 
which reduces H2AX in terminally-differentiated blood cells [82], is unlikely to be the direct target of 
p53 [83]. These are some of the issues that need to be addressed in future studies. 
6. Conclusions  
After serial cell proliferation, normal cells eventually undergo growth arrest (Figure 5). The cells 
may then become quiescent; a state in which cells show largely diminished levels of H2AX under the 
regulation  of the Arf/p53 module.  However, this  state is  abrogated by  exogenous  growth stimuli, 
which cause accelerated entry into S phase and DNA replication stress. Because cells with reduced 
levels of H2AX are defective in DNA damage repair and checkpoint responses, the unrepairable DNA 
lesions are often carried over into M phase and induce tetraploidy. Although most of these tetraploid 
cells are still growth arrested and show a senescent morphology, immortalized cells will appear with 
the Arf/p53 module-mutation, which develops in association with tetraploidization. Thus, normal cells 
generally undergo quiescence when H2AX is downregulated by the Arf/p53 module under conditions 
of  genome  stability,  in  which  cells  maintain  quiescence.  However,  in  the  presence  of  exogenous 
growth stimulation, the development of genomic instability (tetraploidy) and mutations in the Arf/p53 
module lead to the loss of the quiescence and ultimately result in cellular transformation. 
These recent findings illustrate the critical role of H2AX downregulation in the establishment of a 
growth-arrested  cellular  state.  The  phenotypes  of  the  cells  in  this  state  are  often  expressed  in 
association  with  Arf/p53-dependent  downregulation  of  H2AX;  these  include  deficiencies  in  DNA 
repair and checkpoint responses, and an increased risk of genomic instability. Therefore, to avoid cellular 
transformation, genome stability must be maintained in cells after they reach the growth-arrested state 
characterized by H2AX downregulation. 
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